FMTX

Forma Therapeutics Holdings, Inc. [FMTX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

FMTX Stock Summary

In the News

10:38 04 Dec 2022 FMTX

Forma Therapeutics shares jump 50%; here is why

Forma Therapeutics Holdings Inc (NASDAQ: FMTX) shares are up 50% after announcing a definitive agreement with Novo Nordisk.

02:36 04 Dec 2022 FMTX

Why Forma Therapeutics Holdings Stock Is On Fire Today

The rare blood disorder specialist is the latest biotech buyout target.

12:14 04 Dec 2022 FMTX

Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout

Novo Nordisk said Thursday it will spend $1.1 billion to acquire Forma in a deal that sent biotech stock Forma flying. The post Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout appeared first on Investor's Business Daily.

09:20 04 Dec 2022 FMTX

Why Novo Nordisk (NVO) Is Buying Forma Therapeutics (FMTX) For $1.1 Billion

Novo Nordisk (NYSE: NVO) is buying Forma Therapeutics, Holdings Inc (Nasdaq: FMTX) for $1.1 billion. This is why.

08:19 04 Dec 2022 FMTX

Novo Nordisk to acquire Forma Therapeutics in $1.1. billion deal

Danish drugmaker Novo Nordisk will acquire Forma Therapeutics in a deal valued at $1.1 billion to expand its rare blood disorders portfolio, the companies said on Thursday.

08:18 04 Dec 2022 FMTX

Forma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billion

Forma Therapeutics Holdings Inc. FMTX, +1.67% announced Thursday and agreement to be acquired by Denmark-based Novo Nordisk NVO, +0.06% NOVO.B, -0.59% in a deal with an equity value of $1.1 billion. Forma shares are halted for news until 8:30 a.m.

10:32 04 Dec 2022 FMTX

Forma Therapeutics: Rare Disease Play

72% technical buy signal. 15 new highs and up 59.18% in the last month.

10:21 04 Dec 2022 FMTX

Forma Therapeutics Holdings Inc. (FMTX) CEO Frank Lee on Q2 2022 Results - Earnings Call Transcript

Forma Therapeutics Holdings Inc. (NASDAQ:FMTX ) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Adam Bero - Investor Relations Frank Lee - President and Chief Executive Officer Agustin Melian - Executive Vice President, Research and Development Cameron Trenor - Executive Director, Clinical Development Dave Cook - Chief Scientific Officer Todd Shegog - Chief Financial Officer Conference Call Participants Mark Breidenbach - Oppenheimer Maury Raycroft - Jefferies Andrew Berens - SVB Prakhar Agrawal - Cantor Operator Good morning, my name is Josh and I will be your conference operator today. At this time, I would like to welcome everyone to the Forma Therapeutics Second Quarter 2022 Financial Results and Business Update Conference Call.

07:05 04 Dec 2022 FMTX

Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022

11:35 04 Dec 2022 FMTX

Can Forma Therapeutics Holdings, Inc. (FMTX) Climb 536% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 536% in Forma Therapeutics Holdings, Inc. (FMTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

FMTX Financial details

Company Rating
Neutral
Market Cap
957.69M
Income
-190.16M
Revenue
0
Book val./share
8.67
Cash/share
8.28
Dividend
-
Dividend %
-
Employees
189
Optionable
No
Shortable
Yes
Earnings
27 Feb 2023
P/E
-5.24
Forward P/E
-
PEG
-2.16
P/S
-
P/B
2.31
P/C
2.42
P/FCF
-5.46
Quick Ratio
12.29
Current Ratio
12.74
Debt / Equity
0.07
LT Debt / Equity
0.07
-
-
EPS (TTM)
-4
EPS next Y
-
EPS next Q
-
EPS this Y
30.73%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
18.28%
-
-
-
-
SMA20
-45%
SMA50
-8.33%
SMA100
83.33%
Inst Own
0%
Inst Trans
0%
ROA
-40%
ROE
-40%
ROC
-0.43%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
47.86M
Shs Float
33.11M
-
-
-
-
Target Price
20
52W Range
4.95-20.68
52W High
+0.05%
52W Low
+400.25%
RSI
4
Rel Volume
-
Avg Volume
1.55M
Volume
Perf Week
0%
Perf Month
0.3%
Perf Quarter
-
Perf Half Y
251.67%
-
-
-
-
Beta
-0.947609
-
-
Volatility
9.9%, 6.79%
Prev Close
-
Price
20.01
Change
-

FMTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2020-12-31 2021-12-31
Revenue per share
00
Net income per share
-3.05-4.21
Operating cash flow per share
-4.14-3.65
Free cash flow per share
-4.15-3.75
Cash per share
27.4611.3
Book value per share
28.1112.13
Tangible book value per share
28.1112.13
Share holders equity per share
28.1112.13
Interest debt per share
00.8
Market cap
890.69M475.39M
Enterprise value
608M430.71M
P/E ratio
-12.65-2.75
Price to sales ratio
00
POCF ratio
-9.33-3.17
PFCF ratio
-9.31-3.09
P/B Ratio
1.370.95
PTB ratio
1.370.95
EV to sales
00
Enterprise value over EBITDA
-4.16-2.5
EV to operating cash flow
-6.37-2.88
EV to free cash flow
-6.36-2.8
Earnings yield
-0.08-0.36
Free cash flow yield
-0.11-0.32
Debt to equity
00.06
Debt to assets
0.050.11
Net debt to EBITDA
1.930.26
Current ratio
20.6513.86
Interest coverage
00
Income quality
1.360.87
Dividend Yield
00
Payout ratio
00
Sales general and administrative to revenue
00
Research and developement to revenue
00
Intangibles to total assets
00
Capex to operating cash flow
00.03
Capex to revenue
00
Capex to depreciation
-0.2-2.66
Stock based compensation to revenue
00
Graham number
43.9533.89
ROIC
-0.19-0.33
Return on tangible assets
-0.1-0.31
Graham Net
26.5310.01
Working capital
622.75M451.31M
Tangible asset value
00
Net current asset value
621.72M423.7M
Invested capital
00.07
Average receivables
15.27M14.17M
Average payables
4.3M4.22M
Average inventory
00
Days sales outstanding
00
Days payables outstanding
00
Days of inventory on hand
00
Receivables turnover
00
Payables turnover
00
Inventory turnover
00
ROE
-0.11-0.35
Capex per share
-0.01-0.1

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
00000
Net income per share
-0.92-0.91-1.06-0.93-1.1
Operating cash flow per share
-0.69-0.73-0.87-1.04-0.94
Free cash flow per share
-0.69-0.81-0.88-1.04-0.95
Cash per share
11.3110.829.88.868.28
Book value per share
12.2411.4610.529.78.67
Tangible book value per share
12.2411.4610.529.78.67
Share holders equity per share
12.2411.4610.529.78.67
Interest debt per share
0.10.660.690.680.69
Market cap
1.18B1.1B673.86M442.32M329.38M
Enterprise value
1.13B1.04B629.18M399.99M286.79M
P/E ratio
-6.76-6.34-3.36-2.5-1.57
Price to sales ratio
00000
POCF ratio
-36.21-31.56-16.35-8.97-7.36
PFCF ratio
-36.1-28.64-16.18-8.93-7.23
P/B Ratio
2.032.021.350.960.79
PTB ratio
2.032.021.350.960.79
EV to sales
00000
Enterprise value over EBITDA
-25.64-24.21-12.8-9.14-5.49
EV to operating cash flow
-34.79-29.95-15.27-8.11-6.41
EV to free cash flow
-34.69-27.19-15.1-8.07-6.29
Earnings yield
-0.04-0.04-0.07-0.1-0.16
Free cash flow yield
-0.03-0.03-0.06-0.11-0.14
Debt to equity
00.050.060.060.07
Debt to assets
0.060.10.110.10.13
Net debt to EBITDA
1.041.30.910.970.81
Current ratio
17.9416.3913.8616.9512.74
Interest coverage
000-153.66-88.48
Income quality
0.750.80.821.120.85
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.10.010.010.02
Capex to revenue
00000
Capex to depreciation
-0.56-11.34-0.51-0.41-1.12
Stock based compensation to revenue
00000
Graham number
15.9215.3515.8214.2314.65
ROIC
-0.08-0.08-0.1-0.09-0.12
Return on tangible assets
-0.07-0.07-0.09-0.09-0.11
Graham Net
10.849.878.687.967.25
Working capital
526.82M502.25M451.31M420.19M392.98M
Tangible asset value
00000
Net current asset value
523.95M475.49M423.7M393.22M365.77M
Invested capital
0.010.060.070.070.08
Average receivables
14.49M16.38M13.41M13.75M14.56M
Average payables
3.53M3.32M3.09M2.04M2.54M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.08-0.08-0.1-0.1-0.13
Capex per share
0-0.07-0.01-0.01-0.02

FMTX Frequently Asked Questions

What is Forma Therapeutics Holdings, Inc. stock symbol ?

Forma Therapeutics Holdings, Inc. is a US stock , located in Watertown of Ma and trading under the symbol FMTX

Is Forma Therapeutics Holdings, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $20. The lowest prediction is $20 and the highest is $20

What is FMTX stock prediction ?

What is Forma Therapeutics Holdings, Inc. stock quote today ?

Forma Therapeutics Holdings, Inc. stock price is $20.01 today.

Is Forma Therapeutics Holdings, Inc. stock public?

Yes, Forma Therapeutics Holdings, Inc. is a publicly traded company.

Something similar

Same Price Range
Similar Market Cap